FDA advisory panel votes to recommend approval of Moderna’s COVID-19 vaccine
FDA does not have to follow the advice of the panel
Updated:
Tags:
FILE - A man stands outside an entrance to a Moderna, Inc., building, Monday, May 18, 2020, in Cambridge, Mass. A second COVID-19 vaccine moved closer to joining the U.S. fight against the pandemic Thursday, Dec. 17, 2020 as government experts convened for a final public review of its safety and effectiveness. The shot from Moderna and the National Institutes of Health is urgently needed as the country continues to record ever-higher numbers of new cases, hospitalizations and deaths ahead of more holiday travel and family gatherings. FDA s OK is expected shortly after the all-day meeting concludes. (AP Photo/Bill Sikes, file) (Copyright 2020 The Associated Press. All rights reserved)
2nd COVID-19 vaccine by Moderna set for FDA approval in US after panel endorsement
By MATTHEW PERRONE and LAURAN NEERGAARD
Published article
In this photo illustration a medical syringe and a vial depicting fake coronavirus vaccine seen in front of the Moderna US biotechnology company logo. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)
WASHINGTON - A government advisory panel endorsed a second COVID-19 vaccine Thursday, paving the way for the shot to be added to the U.S. vaccination campaign.
The Food and Drug Administration is expected to follow the recommendation for the vaccine from Moderna and the National Institutes of Health. The FDA advisers, in a 20-0 vote, agreed the benefits of the vaccine outweighed the risks for those 18 years old and up.
FDA Advisers Vote To Recommend Moderna For Emergency COVID-19 Vaccine
The Food and Drug Administration is expected to follow the panel s recommendation and approve the second coronavirus vaccine.
Matthew Perrone and Lauran Neergaard
WASHINGTON (AP) A government advisory panel endorsed a second COVID-19 vaccine Thursday, paving the way for the shot to be added to the U.S. vaccination campaign.
The Food and Drug Administration is expected to follow the recommendation for the vaccine from Moderna and the National Institutes of Health. The FDA advisers, in a 20-0 vote, agreed the benefits of the vaccine outweighed the risks for those 18 years old and up.
AP
TribLIVE s Daily and Weekly email newsletters deliver the news you want and information you need, right to your inbox.
WASHINGTON A government advisory panel endorsed a second covid-19 vaccine Thursday, paving the way for the shot to be added to the U.S. vaccination campaign.
The Food and Drug Administration is expected to follow the recommendation for the vaccine from Moderna and the National Institutes of Health. The FDA advisers, in a 20-0 vote, agreed the benefits of the vaccine outweighed the risks for those 18 years old and up.
The FDA’s green light for emergency use is expected quickly. Moderna would then begin shipping millions of doses, earmarked for health workers and nursing home residents, to boost the largest vaccination effort in U.S. history.
E-Mail
IMAGE: Dr. Catherine Van Poznak is the co-chair of a new SWOG Cancer Research Network trial that details, for the first time, the incidence of a common bone disease in cancer. view more
Credit: University of Michigan Rogel Cancer Center
PORTLAND, OR - A landmark study by researchers from the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has found that 2.8 percent of patients on average develop osteonecrosis of the jaw, or ONJ, within three years of starting a common treatment for cancer that has spread to the bone.